Association of artificial intelligence-based immunoscore with the efficacy of chemoimmunotherapy in patients with advanced non-squamous non-small cell lung cancer: a multicentre retrospective study.

Journal: Frontiers in immunology
PMID: 39569187

Abstract

PURPOSE: Currently, chemoimmunotherapy is effective only in a subset of patients with advanced non-squamous non-small cell lung cancer. Robust biomarkers for predicting the efficacy of chemoimmunotherapy would be useful to identify patients who would benefit from chemoimmunotherapy. The primary objective of our study was to develop an artificial intelligence-based immunoscore and to evaluate the value of patho-immunoscore in predicting clinical outcomes in patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Authors

  • Jiaqing Liu
    College of Information Science and Engineering, Ritsumeikan University, Kusatsushi 5250058, Shiga, Japan.
  • Dongchen Sun
    State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Shuoyu Xu
  • Jiayi Shen
    Department of Cardiology, Lishui Central Hospital and the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
  • Wenjuan Ma
    Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huanhuxi Road, Hexi District, Tianjin 300060, China. Electronic address: mawenjuan2008@163.com.
  • Huaqiang Zhou
    Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. liujiaosuan@gmail.com.
  • Yuxiang Ma
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Yaxiong Zhang
    State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Wenfeng Fang
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Yuanyuan Zhao
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Shaodong Hong
    State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Jianhua Zhan
    State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Xue Hou
    State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Hongyun Zhao
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Yan Huang
    Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX.
  • Bingdou He
    Bio-totem Pte Ltd, Suzhou, China.
  • Yunpeng Yang
    Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Li Zhang
    Department of Animal Nutrition and Feed Science, College of Animal Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.

Keywords

External Resources

Popular Topics
Recent Journals